Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Ampio Pharmaceuticals' Stock Soars on Eye Drug for Diabetics


The small-cap drug stock is up on scant information about a trial being ended on a positive outcome.

Shares of Ampio Pharmaceuticals (AMPE) jumped 70% Monday after the company said it stopped a mid-stage study of a drug to treat diabetics with a serious eye disorder because of a positive outcome. While the news sounds promising, the company is providing few details.

The study of patients with diabetic macular edema was being conducted at St. Michael Hospital in Toronto. Researchers concluded a benefit from low doses of the company's pill Optina at four and 12 weeks of study, the company said. There was no benefit using a high dose of the drug, the company adds. Ampio says it will release more details later.

The next step for the suburban Denver company is to discuss with the FDA a final trial for Optina, which Ampio says is an improvement over existing injected treatments. Optina itself is not a new drug. Rather, it's a low-dose form of danazol, a synthetic steroid first approved in the 1970s to treat endometriosis.

Optina is one of three lead products the money-losing company is studying. It's also studying Zertane for premature ejaculation and Ampion for chronic inflammation. Ampion is in early stage testing, while Zertane is farthest along in company studies. The company's focus is largely to find new uses for existing drugs. Ampio doesn't discover its own treatments.

If the name Ampio doesn't resonate, it's because the company has had a short life. Ampio was formed when closely held DMI Life Sciences was merged into over-the-counter shell company Chay Enterprises in early 2010. The new company was rebranded Ampio. In May of last year, the stock began trading on the Nasdaq.

Even with Monday's huge jump in price, the stock is still below its high of more $9 a share (recorded last year). The stock is down by more than a third since its Nasdaq listing last year. After rising more than 70% Monday, the shares were up 57% to $4.20 in early afternoon trading Monday.

DMI founder David Bar-Or is Ampio's chief scientific officer. Bar-Or also heads trauma research at two Denver-area hospitals.

Leading Ampio is Michael Macaluso, a serial entrepreneur and DMI investor. Macaluso became chief executive in January after CEO Donald Wingerter took leave.

Earlier this month, Macaluso articulated his company's approach to bringing new drugs to market.

"I believe drug development is flawed," Macaluso told a Cowen & Co. investor conference. "I think it's very expensive, it's costly, there are a lot of delays. The risk-reward ratios are certainly out of the investor's favor."

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos